(PharmaNewsWire.Com, April 27, 2021 ) According to research report the IVD Quality Control Market is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period.
The In Vitro Diagnostics Quality Control Market is primarily driven by the increasing adoption of third-party quality controls and the rising number of accredited clinical laboratories. However, stringent product approval process and lack of regulations for clinical laboratory accreditation will restrain the market growth.
Based on applications, the IVD quality control market is segmented into clinical chemistry, microbiology, molecular diagnostics, immunochemistry, hematology, coagulation & hemostasis and other applications (ESR, urine chemistry, immunology, cardiac assessment, and blood morphology). The molecular diagnostics segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the rising prevalence of infectious diseases, cancer, and various genetic disorders; the growing demand for blood screening; and the increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing.
On the basis of type, the quality control products market is segmented into serum/plasma-based controls, whole blood-based controls, urine-based controls, and other controls (controls manufactured from spinal fluid, lipoprotein extracts, and immunoproteins). The serum/plasma-based controls segment is expected to account for the largest market share in 2019. The large share of this segment is mainly attributed to the greater uptake of serum/plasma-based quality controls among laboratories and the widening application areas of these controls for various IVD tests.
Recent Developments
> In December 2019, Technopath Clinical Diagnostics (Ireland) and Data Innovations LLC (US) partnered to offer a robust portfolio of quality control data management solutions to their customers. > In October 2019, Thermo Fisher Scientific (US) launched Acrometrix BCR-ABL Panel, a new external molecular quality control panel for the analytical validation of BCR-ABL test methods. > In March 2018, Technopath Clinical Diagnostics (Ireland) and Beckman Coulter Inc. (US) entered into a supply and distribution agreement wherein Technopath supplied its Multichem QC products and IAMQC data management solutions to Beckman Coulter and allowed it to distribute its QC products in more than 100 countries. > In February 2018, Qnostics (UK) and Randox Laboratories Ltd. (UK) entered into a partnership wherein Randox Laboratories to sell and distribute Qnostics’ molecular range of products, which strengthened Qnostics’ market penetration. > In January 2018, Technopath Clinical Diagnostics (Ireland) launched Multichem AMH quality control, a liquid frozen quality control material.
The North America is expected to account for the largest share of the global IVD quality control market in 2020, followed by Europe. The large share of the North America can be attributed to the growing need for ensuring the accuracy and reliability of test results, increasing number of IVD tests, rising use of third-party quality controls among clinical laboratories.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
